Research programme: kinase inhibitors - Nerviano Medical Sciences

Drug Profile

Research programme: kinase inhibitors - Nerviano Medical Sciences

Alternative Names: NMS-088; NMS-P088; NMS-P715; NMS-P948; PHA-680626; PHA-680632

Latest Information Update: 28 May 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Nerviano Medical Sciences
  • Class Small molecules
  • Mechanism of Action Anaplastic lymphoma kinase inhibitors; Aurora kinase A inhibitors; Aurora kinase B inhibitors; Aurora kinase C inhibitors; Bcr-abl tyrosine kinase inhibitors; CDC7 protein kinase inhibitors; Fms-like tyrosine kinase 3 inhibitors; Phosphotransferase inhibitors; Proto oncogene protein c-kit inhibitors; TTK protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 28 May 2018 No recent reports of development identified for preclinical development in Cancer in Italy (PO)
  • 28 Dec 2016 Nerviano Medical Sciences plans clincal trials for NMS P088 in 2017 (Nerviano Medical Sciences pipeline, December 2016)
  • 29 Nov 2016 Pharmacodynamics data from a preclinical studies in Cancer presented at the 28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics(EORTC-NCI-AACR-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top